Daiichi Sankyo

Daiichi gets breakthrough status for pre-NDA leukaemia drug

Quizartinib could have an advantage over rival drug Rydapt. Daiichi Sankyo is gearing up to file its acute myeloid leukaemia (AML) treatment quizartinib in the US, and could now get a ... After a year, survival was 26% with Daiichi Sankyo’s drug and 20%

Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

Meanwhile Daiichi Sankyo is now gearing up to file its acute myeloid leukaemia (AML) treatment quizartinib after it showed extended survival in a phase 3 trial of patients with FLT2-ITD

Abeona Therapeutics appoints new additions to board of directors

Van Duyne, on the other hand, has previously held executive-level business development positions, which led him to serve as global head of business development for Daiichi Sankyo.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]